SGMT - Sagimet Biosciences Inc. Series A Common Stock

SGMT - Sagimet Biosciences Inc. Series A Common Stock

https://www.sagimet.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Sagimet Biosciences Inc. ( SGMT ) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Commentary • 3 weeks, 5 days ago • score: 0.31

Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. ( SGMT )

Zacks Commentary • 3 weeks, 5 days ago • score: 0.28

The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Eupraxia Pharmaceuticals ( NASDAQ:EPRX ) , Braze ( NASDAQ:BRZE )

Benzinga • 1 month, 3 weeks ago • score: 0.14

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Canaccord Genuity analyst Edward Nash initiated coverage on Sagimet Biosciences Inc.

What Makes Sagimet Biosciences Inc. ( SGMT ) a Strong Momentum Stock: Buy Now?

Zacks Commentary • 3 months ago • score: 0.36

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$11.41

52W Low

$1.73

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.38

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.93

EV/Revenue (<3 favorable)

0.28

P/S (TTM) (<3 favorable)

52.50

P/B (<3 favorable)

1.78

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

9.81%

Institutions (25–75% balanced)

29.21%

Shares Outstanding

31,001,100

Float

22,626,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-1.86

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.38%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.4348

Previous

-0.4194

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025